Home » Topics » BioWorld Science

BioWorld Science
RSS

Enanta Pharmaceuticals identifies compounds for RSV infections

Nov. 4, 2019

University of Illinois discloses FOXM1 inhibitors

Nov. 4, 2019

Oligomannate approved in China for mild to moderate AD

Nov. 4, 2019

Neuropore Therapies divulges PIK3C3 inhibitors

Nov. 4, 2019

Promentis Pharmaceuticals announces update on phase II development of SXC-2023

Nov. 4, 2019

OB-002 significantly reduces both primary and metastatic breast cancer in vivo

Nov. 4, 2019

BCX-9250 enters phase I development for treatment of fibrodysplasia ossificans progressiva

Nov. 4, 2019

BGS-2019: a new GMPS inhibitor for the treatment of lupus nephritis

Nov. 4, 2019

Rinvoq meets primary and all ranked secondary endpoints in phase III SELECT-PsA 2 study

Nov. 4, 2019

ORYX announces positive early clinical data for oncolytic virus ParvOryx

Nov. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...